Glucose Health 5/12/2023 Earnings Report

Glucose Health EPS Results

• Actual EPS: -$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Glucose Health Revenue Results

• Actual Revenue: $0.16 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Glucose Health Announcement Details

• Date: 5/12/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Glucose Health (OTCMKTS:GLUC) (OTCMKTS:GLUC) is a digital health company focused on advancing diabetes management through connected medical devices and data-driven insights. Its flagship offering is a smart blood glucose monitoring system that integrates a Bluetooth-enabled glucometer with a companion mobile application. This platform captures, analyzes and transmits real-time glucose readings, enabling patients and healthcare providers to track trends and make more informed treatment decisions.

In addition to its smart meter, Glucose Health has developed proprietary digital biomarkers—algorithms that interpret patterns in glucose fluctuations to predict potential complications. The company provides subscription-based remote patient monitoring services, delivering automated alerts and personalized care plans. These offerings aim to reduce the need for in-person visits, lower healthcare costs and improve outcomes for people living with diabetes.

Founded in 2015 and headquartered in Jacksonville, Florida, Glucose Health has expanded its footprint across the United States and into select international markets, including Canada and parts of Europe. Over the years, it has established partnerships with health systems, physician groups, payers and life sciences companies to integrate its technology into broader care management programs. The company’s go-to-market strategy emphasizes collaboration with telemedicine providers and chronic care management platforms.

Glucose Health is led by a management team of healthcare and technology professionals with decades of combined experience in medical device development, digital therapeutics and population health management. The company continues to invest in research and development, seeking regulatory clearances and clinical evidence to support the efficacy of its digital biomarkers. Its long-term goal is to create a comprehensive ecosystem for chronic disease monitoring that extends beyond diabetes to other metabolic and cardiovascular conditions.